BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med 2017;9:17-25. [PMID: 28553150 DOI: 10.2147/HMER.S113681] [Cited by in Crossref: 66] [Cited by in F6Publishing: 28] [Article Influence: 13.2] [Reference Citation Analysis]
Number Citing Articles
1 Fteah AM, Ahmed AI, Mosaad NA, Hassan MM, Mahmoud SH. Association of MicroRNA 196a and 499 Polymorphisms with Development of Cirrhosis and Hepatocellular Carcinoma Post-HCV Infection in Egyptian Patients. Asian Pac J Cancer Prev 2019;20:3479-85. [PMID: 31759375 DOI: 10.31557/APJCP.2019.20.11.3479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology 2019;156:492-509. [PMID: 30404026 DOI: 10.1053/j.gastro.2018.11.001] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 16.3] [Reference Citation Analysis]
3 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Abdelgaid HA, El-desouky MA, Ibrahim KA, Fahmi AA, Amin AI. Diagnostic sensitivity of arginase, alpha-1 antitrypsin and alpha-fetoprotein in hepatitis patients. Highlights in BioScience. [DOI: 10.36462/h.biosci.202111] [Reference Citation Analysis]
5 Farrag HM, Monir MS, Abdel-Dayem WS, Ali HA, Ibrahim AM. Global longitudinal strain as a predictor of short-term effect of oral antiviral regimens on myocardium in Egyptian patients with chronic viral hepatitis C. Egypt Heart J 2021;73:6. [PMID: 33420861 DOI: 10.1186/s43044-020-00129-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
7 Kamal A, Ramadan A, Sherief D, Hassan A, Nosair N, Mabrouk M, Habeeb E, Haydra T. Relation between levels of toll-like receptors 3 and 7 and clinical profile of Child-Pugh B cirrhotic patients. Clin Exp Hepatol 2021;7:293-6. [PMID: 34712831 DOI: 10.5114/ceh.2021.109336] [Reference Citation Analysis]
8 Tag-Adeen M, Sabra AM, Akazawa Y, Ohnita K, Nakao K. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement. Hepat Med. 2017;9:45-53. [PMID: 29062242 DOI: 10.2147/hmer.s142600] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kohla MAS, Fayoumi AE, Akl M, Abdelkareem M, Elsakhawy M, Waheed S, Abozeid M. Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy. Clin Exp Med 2020;20:143-8. [PMID: 31792631 DOI: 10.1007/s10238-019-00597-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Mohamed HZ, Sabri NA, Zaki HM, Shaheen SM. Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A randomized, placebo-controlled, double-blinded study. Clin Exp Hepatol 2020;6:99-105. [PMID: 32728626 DOI: 10.5114/ceh.2020.95566] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Behairy BE, El-Araby HA, El-Guindi MA, Basiouny HM, Fouad OA, Ayoub BA, Marei AM, Sira MM. Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. J Pediatr 2020;219:106-10. [PMID: 32008767 DOI: 10.1016/j.jpeds.2019.12.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Ali ME, El-Badawy O, Afifi NA, Eldin AS, Hassan EA, Halby HM, El-Mokhtar MA. Role of T-Helper 9 Cells in Chronic Hepatitis C-Infected Patients. Viruses 2018;10:E341. [PMID: 29937515 DOI: 10.3390/v10070341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
13 El Kassas M, Hegazy OM, Salah EM. Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations. World J Hepatol 2020; 12(10): 841-849 [PMID: 33200021 DOI: 10.4254/wjh.v12.i10.841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Yehia SA, Morad WS, Hendy OM, Dorgham LS. Effect of health education intervention on hepatocellular carcinoma risk factor prevention in Menoufia governorate, Egypt. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-019-0011-x] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 El Kassas M, Alboraie M, Naguib M, Omar H, Tahan AE, Moaz I, Abdellah M, Ezzat S, Wifi MN, Sherief AF, Eltabbakh M, Abdelsalam L, Eissa AH, Omran D. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019;30:708-13. [PMID: 31418415 DOI: 10.5152/tjg.2019.18514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Douglass CH, Pedrana A, Lazarus JV, 't Hoen EFM, Hammad R, Leite RB, Hill A, Hellard M. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med 2018;16:175. [PMID: 30296935 DOI: 10.1186/s12916-018-1162-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
17 Abbasy M, Zaghla H, Elhelbawy M, Ramadan M, Zakareya T. Predicting in-hospital mortality of cirrhotic patients hospitalized with hepatic encephalopathy. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00178-z] [Reference Citation Analysis]
18 Teama NM, Abdel-mohsen WA, Ahmed OA, El Sayed SM, Elghandour AM. Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00079-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mogahed EA, Sayed AA, Khalifa SE, El-Hennawy A, El-Raziky MS. Causes of secondary non-alcoholic fatty liver disease in non-obese children below 10 years. Eur J Pediatr 2020;179:719-26. [PMID: 31897838 DOI: 10.1007/s00431-019-03551-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 El-Ghitany EM, Farghaly AG. Geospatial epidemiology of hepatitis C infection in Egypt 2017 by governorate. Heliyon 2019;5:e02249. [PMID: 31463388 DOI: 10.1016/j.heliyon.2019.e02249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Zakareya T, Akl M, Shibl S, El-mazaly M, Abdel-razek W. Utility of prognostic scores in predicting short-term mortality in patients with acute-on-chronic liver failure. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00183-2] [Reference Citation Analysis]
22 Bendas ER, Rezk MR, Badr KA. Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers. Clin Drug Investig 2018;38:439-48. [PMID: 29417463 DOI: 10.1007/s40261-018-0622-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ehsan N, Sweed D, Elsabaawy M. Evaluation of HCV-related liver fibrosis post-successful DAA therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00129-0] [Reference Citation Analysis]
24 Ferreira VL, Leonart LP, Tonin FS, Borba HHL, Pontarolo R. Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies. Clin Drug Investig 2018;38:389-400. [PMID: 29435907 DOI: 10.1007/s40261-018-0624-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
25 Ismail IT, Fiehn O, Elfert A, Helal M, Salama I, El-Said H. Sugar Alcohols Have a Key Role in Pathogenesis of Chronic Liver Disease and Hepatocellular Carcinoma in Whole Blood and Liver Tissues. Cancers (Basel) 2020;12:E484. [PMID: 32092943 DOI: 10.3390/cancers12020484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Motawi TMK, Sadik NAH, Sabry D, Shahin NN, Fahim SA. rs2267531, a promoter SNP within glypican-3 gene in the X chromosome, is associated with hepatocellular carcinoma in Egyptians. Sci Rep 2019;9:6868. [PMID: 31053802 DOI: 10.1038/s41598-019-43376-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Schwander B, Feldstein J, Sulo S, Gonzalez L, ElShishiney G, Hassany M. Pursuing Elimination of Hepatitis C in Egypt: Cost-Effectiveness and Economic Evaluation of a Country-Wide Program. Infect Dis Ther 2022. [PMID: 35451742 DOI: 10.1007/s40121-022-00631-x] [Reference Citation Analysis]
28 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Reference Citation Analysis]
29 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
30 El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action. World J Diabetes 2021; 12(9): 1401-1425 [PMID: 34630897 DOI: 10.4239/wjd.v12.i9.1401] [Reference Citation Analysis]
31 Maghrabi HME, Elmowafy AY, Refaie AF, Elbasiony MA, Shiha GE, Rostaing L, Bakr MA. Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients. Int Urol Nephrol 2019;51:2295-304. [PMID: 31531807 DOI: 10.1007/s11255-019-02272-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Zakareya T, Elhelbawy M, Elzohry H, Eltabbakh M, Deif M, Abbasy M. Long-Term Impact of Hepatitis C Virus Eradication on Liver Stiffness in Egyptian Patients. Can J Gastroenterol Hepatol 2021;2021:4961919. [PMID: 34589447 DOI: 10.1155/2021/4961919] [Reference Citation Analysis]
33 El Kassas M, Eltabbakh M, Elbadry M, Tawheed A, Elbaz T. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Curr Med Res Opin 2022;:1-23. [PMID: 35118916 DOI: 10.1080/03007995.2022.2038489] [Reference Citation Analysis]
34 El-Araby ME, Omar AM, Soror SH, Arold ST, Khayat MT, Asfour HZ, Bamane F, Elfaky MA. Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease. J Adv Res 2020;24:251-9. [PMID: 32373358 DOI: 10.1016/j.jare.2020.01.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Hassanin A, Kamel S, Waked I, Fort M. Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study. Glob Health Sci Pract 2021;9:187-200. [PMID: 33795369 DOI: 10.9745/GHSP-D-20-00234] [Reference Citation Analysis]
36 Ahmed MM, O Shaarawy H, Anwar I, Sarhan MD. Barriers to Completing Therapy for Hepatitis C with Direct-Acting Antivirals: A Real-Life Experience from a Single Treatment Center in Egypt. J Prim Care Community Health 2021;12:21501327211008051. [PMID: 33813925 DOI: 10.1177/21501327211008051] [Reference Citation Analysis]
37 Alian SM, Wahba MO, Gomaa AF, Khalil SS. The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis. Egypt Rheumatol Rehabil 2020;47. [DOI: 10.1186/s43166-020-00021-6] [Reference Citation Analysis]
38 Waked I. Case study of hepatitis C virus control in Egypt: impact of access program. Antivir Ther 2022;27:13596535211067592. [PMID: 35491550 DOI: 10.1177/13596535211067592] [Reference Citation Analysis]
39 Hemeda AA, Ahmad Mohamed A, Aziz RK, Abdel-Hakeem MS, Ali-Tammam M. Impact of IL10, MTP, SOD2, and APOE Gene Polymorphisms on the Severity of Liver Fibrosis Induced by HCV Genotype 4. Viruses 2021;13:714. [PMID: 33924242 DOI: 10.3390/v13040714] [Reference Citation Analysis]
40 Omar AM, Elfaky MA, Arold ST, Soror SH, Khayat MT, Asfour HZ, Bamane FH, El-Araby ME. 1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease. Biomolecules 2020;10:E479. [PMID: 32245218 DOI: 10.3390/biom10030479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, Fouad R, Elsharkawy A, Hammad R, Abdel-Razek W, Zakareya T, Kersey K, Massetto B, Osinusi A, Lu S, Brainard DM, McHutchison JG, Waked I, Doss W. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut 2019;68:721-8. [PMID: 29666174 DOI: 10.1136/gutjnl-2017-315906] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
42 Eletreby R, Elraouf MA, Fouad A, Nasser M, Al Bassiouni M, Zayed N, Yosry A, Abdellatif Z. Screening for chronic hepatitis C and chronic hepatitis B infections among pregnant females: a cross-sectional study. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00113-8] [Reference Citation Analysis]
43 Mohamed EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, Ghareeb DA, Ross B. Electronic nose versus quadrupole mass spectrometry for identifying viral hepatitis C patients. J Viral Hepat 2022;29:147-55. [PMID: 34773341 DOI: 10.1111/jvh.13630] [Reference Citation Analysis]
44 Talaat M, Afifi S, Reaves EJ, Abu Elsood H, El-Gohary A, Refaey S, Hammad R, Abdel Fadeel M, Kandeel A. Evidence of sustained reductions in the relative risk of acute hepatitis B and C virus infections, and the increasing burden of hepatitis a virus infection in Egypt: comparison of sentinel acute viral hepatitis surveillance results, 2001-17. BMC Infect Dis 2019;19:159. [PMID: 30764780 DOI: 10.1186/s12879-019-3806-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Zaafan MA, Abdelhamid AM. Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt/β-catenin and TGF-β/smads pathways. J Enzyme Inhib Med Chem 2022;37:118-24. [PMID: 34894966 DOI: 10.1080/14756366.2021.1995379] [Reference Citation Analysis]
46 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Reference Citation Analysis]